Cambridge/London – DNA-targeted therapeutics specialist Spirogen Ltd. is partnering with Roche’s Genentech Inc. unit to discover and develop antibody drug conjugates (ADCs) as anticancer therapeutics using Spirogen’s pyrrolobenzodiazepine antibiotics and associated linker technology. The UK firm will be responsible for synthesising and manufacturing drug reagents, while Genentech will generate antibody drug conjugates and evaluate their potential therapeutic utility. Genentech will have exclusive rights for further development and commercialisation. Spirogen will receive an initial
license fee and is eligible for milestones and royalties. Further terms of the deal were not disclosed.